Twist Bioscience Q2 Revenue Jumps 19%, Inks $33.8M Invenra Antibody Discovery Deal
Summary
Twist Bioscience reported second-quarter 2026 revenue of $110.72 million, marking a 19.3% increase year-over-year, though it also posted an increased net loss of $44.02 million and a diluted EPS loss of $0.71. Crucially, the company announced a new strategic co-exclusive license agreement with Invenra, accompanied by a $33.8 million equity investment, aimed at expanding its bispecific antibody discovery capabilities. This 10-Q summary follows an 8-K filing earlier today that announced record second-quarter revenue and raised full-year fiscal 2026 revenue guidance. While the core earnings figures were likely disclosed in the 8-K, the Invenra partnership appears to be new, material information from the detailed 10-Q. The strong revenue growth and strategic expansion into antibody discovery are positive developments, despite the increased net loss. Investors will be watching the execution of this partnership and its contribution to future growth and profitability.
At the time of this announcement, TWST was trading at $56.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4B. The 52-week trading range was $23.30 to $66.06. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.